SRX Global Inc.
No enriched coverage for $SRXH in the last 7 days.
No SEC Form 4 filings for $SRXH in the last 30 days.
See all $SRXH insider activity →SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on August 27, 2026, SRX Global Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (“Buye
SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers The Debt investment is expected to accelerate development of CERo’s lead t
SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Private Placement Securities Purchase Agreement On August 27, 2026, SRX Global Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accre
Recent SRXH coverage spans corporate actions, earnings and financial news.
The capital raise and repurchase authorization could provide liquidity and support the share price.
The investment provides CERo with capital and may boost SRX's portfolio value.
The capital raise dilutes existing shareholders but provides cash; price may move modestly higher on funding news.
Positive cash position and dividend may support the stock, but modest earnings and ongoing losses limit upside.
Stake acquisition and engagement intent can support sentiment, but without disclosed size or terms it is less actionable than a formal deal.
AlphAI scores every news story that mentions SRXH with an AI model for sentiment and relevance, and aggregates insider trades from SRX Global Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on August 27, 2026, SRX Global Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (“Buye
1 min readSRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers The Debt investment is expected to accelerate development of CERo’s lead t
2 min readSRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Private Placement Securities Purchase Agreement On August 27, 2026, SRX Global Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accre
1 min readSRX Global Inc. (SRXH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SRX GLOBAL INC. ANNOUNCES FISCAL THIRD QUARTER 2026 FINANCIAL RESULTS Net Asset Value (“NAV”) of $62.9 million, or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricte
2 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readSRX Global Inc. (SRXH) said it acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage neuroscience biopharma developing intranasal “pherines” for CNS disorders. SRXH said it views VTGN as undervalued and plans constructive engagement with management and the board. VTGN closed at $0.24 and was $0.37 in pre-market.
3 min readSRX Global Inc. (SRXH) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001471727 0001471727 2026-07-27 2026-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
2 min readSRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001471727 0001471727 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
3 min readSRX Global Inc. (NYSE American: SRXH) reported paper-traded EMJX crypto-treasury returns of about 24.8% (time-weighted) from Feb. 11 to July 10, 2026, versus Bitcoin at -4.2% over the same period. The EMJX regime model shifts among Bull, Mixed, and Stress and will start trading with real capital after an acquisition. Management plans a July 14 fireside chat.
3 min readSRX Global, Inc. (NYSE American: SRXH) said CEO Kent Cunningham and President Eric Jackson will host a virtual fireside chat on July 14, 2026 at 10:30 a.m. ET to discuss developments and the completed EMJX acquisition. In a shareholder letter, the company cited $55 million+ cash and short-term investments, no debt, net asset value about $3.07 per share, plus a repurchase plan for up to 10 million shares and a dividend totaling about $1 million.
4 min read
